Abstract

Introduction: Pregnancy in people with inflammatory bowel disease (IBD) is associated with a higher risk of adverse outcomes compared to the general population. Identification of clinical factors which predict flares could be used to guide treatment decisions. Our aim was to identify clinical predictors of disease flares in pregnant people with IBD. Methods: A retrospective cohort study of all deliveries from 1/1/2011 to 1/1/2020 at an academic tertiary care medical center in a major metropolitan area in the United States. Pregnant people were identified using ICD-9 codes for IBD and CPT codes for deliveries. Charts were reviewed for baseline demographics, obstetric history, disease subtype (Crohn’s disease [CD] or ulcerative colitis [UC]), medication use, disease course and adverse outcomes during pregnancy. Results: 42,000 deliveries were identified of which 122 were in those with IBD of whom 33% (n = 40) flared during pregnancy. UC diagnosis was associated with higher risk of pregnancy flare compared to CD (55% vs 22.4% p=0.001). Elevated stool calprotectin was associated with higher risk of pregnancy flare (564.4 vs 37.6 p=0.007). Patients on thiopurines and combination therapy with a biologic had fewer flares than those on no medications, 5-ASAs, biologics alone or steroids (p< 0.05). Pregnant people in endoscopic or clinical remission prior to pregnancy had significantly fewer disease flares compared to those who did not (p=0.0001). Pregnant people who flared had significantly higher rates of preterm premature rupture of membranes (PPROM 10.5% vs 1.3% p=0.04) and small for gestational age offspring (12.8% vs 2.6% p=0.04) compared to those who did not experience a peripartum flare (Table 1). Rate of other adverse obstetric and neonatal outcomes did not differ between groups (Table 1). A logistic regression model utilizing clinical, endoscopic remission, and calprotectin resulted in 85.7% accuracy for prediction of flares. Conclusion: In our population of pregnant people with IBD, disease flares during pregnancy were associated with higher rates preterm premature rupture of membranes and small for gestational age offspring. Clinical and endoscopic remission along with calprotectin data may be sufficient to predict disease flares during pregnancy and assist in counseling and treating this group of patients to maximize optimal pregnancy outcomes.Table 1.: Patient Characteristics and Outcomes.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.